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Vascular leakage is a serious side effect of therapies based
on monoclonal antibodies or cytokines which may lead to life-
threatening situations. With the steady increase of new drug de-
velopment programs for large molecules, there is an urgent need
for reliable tools to assess this potential liability of new medicines
in a rapid and cost-effective manner. Using human umbilical vein
endothelial cells (HUVECs) as a model for endothelium, we estab-
lished an impedance-based assaymeasuring the integrity of the en-
dothelial cell monolayer in real time. We could demonstrate that
the HUVECmonolayer in our system was a relevant model as cells
expressed major junctional proteins known to be responsible for
maintaining tightness as well as receptors targeted by molecules
known to induce vascular leakage in vivo. We assessed the time-
dependent loss of barrier function using impedance and confirmed
that signals obtained corresponded well to those from standard
transwell assays. We assayed a series of reference molecules which
led to the expected change of barrier integrity. A nonspecific cyto-
toxic effect could be excluded by using human fibroblasts as a non-
responder cell line. Finally, we could show reversibility of vascu-
lar permeability induced by histamine, IL-1, or TNF- by coin-
cubation with established antagonists, further demonstrating rel-
evance of this new model. Taken together, our results suggest that
impedance in combination with HUVECs as a specific model can
be applied to assess clinically relevant vascular leakage on an in
vitro level.
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The inner layer of the vascular wall is constituted of endothe-
lial cells that represent the physical barrier between blood and
interstitial tissue. Endothelial cells are closely connected with
their neighboring cells by so-called tight and adherens junctions
which are responsible for maintaining the tightness of the vascu-
lature (Vandenbroucke et al., 2008). Thus, modulation of these
junctions has a direct impact on the permeability of the vascula-
ture. For example, during inflammatory processes in the body a
release of proinflammatory cytokines can lead to an impairment
of the vascular barrier function (Aghajanian et al., 2008; Dudek
and Garcia, 2001) and lead to vascular leak syndrome (VLS)
either by direct or by cell-mediated mechanisms. Other vasoac-
tive substances, such as histamine and thrombin, can also affect
the stringency of the endothelial barrier and can also trigger sig-
naling cascades that downregulate tight and adherens junction
proteins and cytoskeletal remodeling (Aghajanian et al., 2008).
These processes weaken endothelial cell connections and lead
to a separation of cells and looseness of the barrier for a lim-
ited time. Reduced integrity of the vascular endothelial mono-
layer then finally causes a leakage of fluid from the circula-
tory system into the interstitial space which results in interstitial
edema, decrease in microcirculatory perfusion, deprivation of
intravasal volume and eventually to organ dysfunction, and in
an extreme case systemic shock (Bazzoni, 2006; Capaldo and
Nusrat, 2009).
Although observed under selected pathological conditions,
vascular leakage can also occur during infusion reactions af-
ter administration of monoclonal antibodies or cytokines. Al-
though reversible when managed early enough, this may lead to
a life-threatening response as seen in patients who suffered from
cytokine storm after receiving the superagonistic anti-CD28 an-
tibody TGN1412 during a phase I trial (Suntharalingam et al.,
2006). It has been shown that VLS is one of the dose-limiting
side effects of IL-2 in cancer patients or HIV patients receiv-
ing highly active antiretroviral therapy (Baluna, 2007; Kovacs
et al., 1995; Lotze et al., 1986; Siegel and Puri, 1991). Because
preclinical safety characterization of therapeutic cytokines and
monoclonal antibodies becomes increasingly more important
during development, there is a need for systems with the po-
tential to assess vascular leakage early on. Today’s standard as-
say to measure vascular permeability induced by drugs is by
comparing diffusion rates of a dye through a monolayer of an
endothelial cell of treated and untreated cells (Ludwig et al.,
2011). Although technically correct, this assay is cumbersome
and its throughput is low.
The goal of the present study was to design an in vitro system
based on human umbilical vein endothelial cells (HUVECs) as
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a model to assess the potential of drug candidates to induce vas-
cular leakage. By using an impedance-based approach, we were
aiming at measuring drug-induced effects affecting the tight-
ness of endothelial cell-cell junctions although passage of fluid
or macromolecules were only indirectly reflected by the read-
out. We herein demonstrate that our impedance-based platform
captures monolayer changes associated with disruption of tight
and adherens junctions which are in full agreement to those cap-
tured by passive diffusion of FITC (Fluorescein isothiocyanate)
-coated beads in a transwell chamber. In addition, this nonin-
vasive method allows real-time kinetics, dose-effect compari-
son, parallel recording of different treatments, and semiquanti-
tative assessment relative to controls in a very easy and efficient
way. Specifically, we analyzed eight different cytokines and va-
soactive substances, and our impedance-based results concord
with literature reports. Importantly, we also demonstrate that
the impedance-based assay was able to monitor the reversibil-
ity of the vascular leakage induced by IL-1, TNF-, or his-
tamine when applying selective antagonists such as anakinra,
remicade, clemastine, and methylprednisolone. Taken together,
in the present study we could establish an easy and robust sys-
tem that is able to assess vascular leakage in a real-time fashion.
This system could be of importance for the pharmaceutical in-
dustry not only to screen drugs early on for their potential to
induce vascular leakage in humans but also to select for the best
antidote treatment or to perform mechanistic investigations.
MATERIALS AND METHODS
Material. HUVECs and specific culture medium (EGM2)
were purchased from Lonza. Thrombin and histamine were pur-
chased from Sigma-Aldrich and human recombinant cytokines
were purchased from rnd systems, with the exception of IFN-
from Roche. Antagonists as methylprednisolone (brand name:
Solu-Medrol) were purchased from Pfizer, clemastine (brand
name: Tavegil) from Novartis, anakinra (brand name: Kineret)
from Sobi, Infliximab (brand name: Remicade) from Janssen
Biotech, E-Plates View from Roche Applied Science and Col-
lagen I, and rat tail from BD.
Cell culture. HUVECs were cultured at 37◦C, 5% CO2, and
95% humidity in EGM2 medium (Lonza) until they reached a
confluency of maximal 80% and subsequently subcultivated.
All experiments were performed with cells between passages
2 and 8. Human fibroblast cell line CCD25-SK (ATCC CRL-
1474) was grown in MEM (Minimum Essential Media) (Gibco)
containing 10%FCS (Fetal Calf Serum) and 2mML-Glutamine.
Medium was exchanged every other day and cells were subcul-
tured before they reached complete confluence.
Transwell assay for vascular permeability. To analyze a
thrombin-induced increase in endothelial permeability, HU-
VECs were grown on collagen-coated transwell inserts with a
pore size of 0.4 m (Millipore). For collagen coating, filters
were incubated with 200 l 50 g/ml rat tail collagen (BD)
for 1 h at room temperature. Before cells were seeded, inserts
were washed once with phosphate buffered saline (PBS). Cul-
tures were grown to complete confluence, controlled by visual
inspection which was normally after one week. During this pe-
riod medium was changed every other day. To measure tran-
swell permeability, 150 kDa FITC-labeledDextran (Fluorescein
isothiocyanate–dextran, Sigma) was added to a final concentra-
tion of 7.5 g/well to the upper part of the transwell system. At
60 and 30 min before thrombin was added, samples were taken
for measuring baseline transwell permeability, each 10 l in
triplicates from the lower chamber. Samples were transferred to
a black wall 384 multiwell plate for final fluorescence analysis.
Afterward thrombin was added to the upper part of the transwell
insert to a final concentration of 20 U/ml. Following thrombin
treatment, three samples were taken at 0, 30, 45, 60, 75, 120,
150, and 210 min for each well and were again transferred to a
384well plate for later fluorescencemeasurement. Fluorescence
was measured using an Envision Plate reader (Perkin Elmer) at
488 nm excitation and 555 nm Emission. Slope was determined
from mean fluorescence values of three technical replicates be-
tween two adjacent time points for each experiment separately.
Each experiment was done in triplicate and data are displayed as
slope ± standard deviation for untreated and thrombin-treated
HUVECs separately.
High content image analysis for cell death. To determine the
amount of dead cells at the end of the impedance experiment, a
LIVE/DEAD fixable cell stain (Life Technologies) was used
in combination with high content imaging on an Array Scan
VTi Platform (Thermo Fisher). LIVE/DEAD assay was used
as recommended by the vendor (Invitrogen). Briefly HUVECs,
24 h after the final addition of the antagonist, were washed with
PBS (Life Technologies) and then incubated with the reconsti-
tuted dye diluted 1:1000 in Hank’s balanced salt solution (Life
Technologies) for 30 min at room temperature and in the dark.
Afterward cells were washed, fixed for 15 min with 4% PFA
(Paraformaldehyde 16% Alfa Aesar, 1:4 in PBS), and cell nu-
clei were counterstained with Hoechst 33342 (diluted 1:2000
in PBS; Life Technologies). Afterward the E-Plate View was
imaged using a x20 magnification and analyzed using the Tar-
get Activation Bioapplication with Hoechst in channel 1 as ob-
jects with BGRFR 386 filters. In channel 2, nuclear fluores-
cence intensity of LIVE/DEAD cell stain was assessed with
BGRFR 485 filters. Percent positive responders for dead cells
were calculated from cells identified as objects in channel 1 (nu-
clei) and showing a mean total intensity above 50,000 in chan-
nel 2 (dead cell stain). Results were calculated as the average of
four analyzed wells, in each well 28 fields were analyzed and
displayed as the percentage of dead cells ± standard deviation.
xCELLigence assay for vascular permeability. For
impedance analysis, HUVECs or CCD25-SK were seeded
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on E-Plates View (Roche Applied Science) at a density of
2,000 cells/well or 2500 cells/well, respectively. During
the following seven days, cells were grown to confluence
indicated by a plateau of the impedance curve. During that time
medium was changed every other day and impedance termed
“cell index” (CI) was measured every 15 min. HUVECs or
CCD25-SK were treated with cytokines or other compounds
at three different concentrations as indicated in the graphs
and the Results section. After treatment, impedance was
measured every 2 min for the following 12 h. All HUVEC
experiments were done with two different batches of HUVECs.
For analysis, impedance values were calculated as baseline
normalized impedance as follows: for each time point average
impedance value of untreated controls was subtracted and
normalized as CI(normalized) = CItime x / CInorm time (termed here
“baseline normalized CI”). This baseline normalized CI was
used for graphical result representation using Microsoft Excel
2010. Results were displayed as the average of four or six
independent wells treated with the indicated compounds and
for Figures 1C and 1D ± standard deviation.
For rescue/inhibition experiments, HUVECs were cultivated
as mentioned above. At time point 1 (see Fig. 4), eight wells
were treated with “inhibitors” anakinra (final concentration 1
g/ml), Remicade (final concentration 200 g/ml), Tavegil
(final concentration 700 ng/ml), or Methyl-Prednisolone (final
concentration 40 g/ml). At time point 2, a subset of 4 wells of
the previously 8 treated wells, IL-1, histamine, or TNF- was
added and eight additional wells were treated with IL-1, TNF,
and histamine alone. Impedance analysis was continued for the
following 12 h. Then, impedance measurements were paused
and four of the eight wells, treated with histamine, IL-1, or
TNF- before, were now treated with the corresponding antag-
onists in the same concentration as mentioned above. E-Plates
were put back into the incubator and impedance measurements
were continued for the following 12 h. At the end of the ex-
periments, E-Plates were further processed for a LIVE/DEAD
assay as mentioned above. Finally impedance values were cal-
culated as mentioned above except for baseline CI calculation.
For calculation of baseline CI, impedance values of the corre-
sponding antagonist alone were used as control values. Data
were transferred to Microsoft Excel and graphs represent av-
erage values of four replicates.
Immunocytochemistry and microscopy. For immunocyto-
chemistry experiments, cells were seeded on collagen-coated
eight-well chamber slides (10 g/cm2 rat tail collagen for
1 h at room temperature; BD Falcon) at a density of 2000
cells/chamber. Cells were grown until they reached complete
confluence that was after eight days andmediumwas exchanged
every other day. Cells were treated with thrombin (20 U/ml) for
30 min whereas controls were left untreated. For immunocy-
tochemistry, cells were washed once with PBS and afterward
fixed with 2% PFA for 5 min at room temperature and then
washed once with PBS and permeabilized for 5 min with 0.1%
PBST (PBS, Triton-X 100 added 0.1% v/v) and blocked for
30 min with 10% normal goat serum in PBS. First antibody
was diluted in PBS (Claudin 5 1:100, ZO-1 1:100, and VE-
Cadherin 1:50) incubated overnight at 4◦C and after three wash-
ing steps with PBS secondary antibody Alexa 488 or 555 anti-
mouse (1:200 in PBS) was added for 1 h at room temperature.
After three final washing stepswith PBS slides were coversliped
with ProlongGoldAntifade (Invitrogen) containingDAPI (4′,6-
Diamidin-2-phenylindol) as a nuclear stain. For actin staining
slides were incubated with Alexa 647 labeled Phalloidin as
recommended by the manufacturer (Invitrogen). Images were
taken with a confocal microscope (DMI 4000B, Leica) at x40
magnification and are displayed as projections of multiple Z-
layers. Specificity of antibody staining was proven by omitting
primary antibodies for control samples and incubation with sec-
ondary antibody only. This procedure did not reveal any unspe-
cific staining for all secondary antibodies used in the present
study.
Gene expression analysis in HUVECs. Total RNA from cells
was extracted using the RNeasy Mini kit combined with DNase
treatment on a solid support (Qiagen). RNA quality assess-
ment and quantification was performed using microfluidic chip
analysis on an Agilent 2100 bioanalyzer (Agilent Technolo-
gies). Five micrograms of total RNA was reverse transcribed
using the Roche cDNA Synthesis System. After silica adsorp-
tion column purification, double-stranded cDNA was labeled
with Cy3 using the Roche NimbleGen One Color DNA La-
beling Kit. NimbleGen 12 × 135K gene expression microar-
rays (100718 HG18 opt expr) were hybridized with 4 g of
Cy3-labeled cDNA for 16 h at 42oC and were washed and
dried according to the manufacturer’s instruction. Microarray
data were collected by confocal scanning using the Roche
NimbleGen MS200 Microarray Scanner at 2 m pixel reso-
lution (Roche NimbleGen). NimbleGen probe intensities were
subjected to background correction, quantile normalization,
and robust multiarray analysis as implemented in the Nim-
bleScan Software, version 2.6 (Roche NimbleGen). Averaged
gene-level signal intensities were summarized into gene calls
and log2 transformed. The microarray data from this study
have been deposited at the NCBI Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) under the accession num-
ber GSE52044.
RESULTS
Thrombin-Induced Redistribution of Tight and Adherens
Junction Proteins
Tight and adherens junctions are key tomaintaining and regu-
lating the tightness of the endothelium.We investigated whether
HUVECs were able to successfully establish tight and adherens
junctions in vitro and whether those are affected by throm-
bin, a well-known vasoactive substance. Figure 1 shows the
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FIG. 1. Expression of junctional proteins: Immunocytochemistry of ZO-1, VE-Cadherin, and Claudin 5 on HUVECs with or without treatment of 20 U
thrombin for 30 min (A1)–(D2) or CCD25-SK human fibroblasts (E)–(H). ZO-1, VE-Cadherin, and Claudin 5 staining clearly outline cell membranes of untreated
HUVECs and actin staining is mostly restricted to the periphery of cell bodies (A1)–(D1). Thirty minutes after thrombin incubation, the ZO-1, VE-Cadherin, and
Claudin 5 staining pattern is fragmented and actin stain shows a lot of filaments now located additionally at the center of the cell body (A2)–(D2). CCD25-SK
human fibroblasts do not show any expression of ZO-1, VE-Cadherin, or Claudin 5 at cell membranes, and cells show a positive immunoreactivity for actin
(E)–(H). Controls where primary antibody has been omitted do not show any unspecific binding. Scale bar = 25 m.
expression pattern of three junctional proteins: VE-Cadherin,
an adherens junction protein; Claudin 5, a tight junction pro-
tein; and ZO-1, a linker protein that links the tight junction pro-
teins to the actin cytoskeleton (Vandenbroucke et al., 2008).
Under untreated conditions (Figs. 1A1–D1), tight and adherens
junctional proteins were perfectly aligned along the cell mem-
brane between neighboring HUVECs. Actin staining was con-
centrated at the periphery of each cell whereas the center around
the nucleus did not show a pronounced actin staining. Throm-
bin was used as a positive control which is known to induce
changes in vascular permeability (Baumer et al., 2008; Rabiet
et al., 1996). Thirty minutes after thrombin was added, the ex-
pression pattern of the junctional proteins and actin changed
significantly (see Figs. 1A2–D2). Staining of junctional pro-
teins was not any longer aligned along membranes but was frag-
mented and even punctiform, signaling a disruption in the lin-
ing integrity and suggesting leakiness of the monolayer. Actin
staining revealed an increase in actin positive fibers now as well
present in the center of the cell. As expected, staining for ZO-
1, VE-Cadherin, and Claudin 5 was negative along the mem-
brane of CCD25-SK cells (Figs. 1E–G) confirming the absence
of functional tight and adherens junction proteins in these fi-
broblasts.
Increase in Vascular Permeability Is Reflected by Decrease in
Impedance
The next step was to investigate if impedance-based readout
could monitor alterations of the vascular permeability induced
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by thrombin. In contrast to the transwell assay, where an in-
crease in permeability would lead to an increase in diffusion of
a dye, an increase in vascular permeability would lead to a de-
crease in impedance in the presented system.We analyzed diffu-
sion of FITC-labeledDextran in a transwell assaywith andwith-
out thrombin treatment and compared the results to those of the
impedance assay. Diffusion of FITC-labeled Dextran through a
confluent HUVEC monolayer did increase directly after treat-
ment with thrombin whereas diffusion in untreated HUVECs
was stable over all (see Fig. 2A). Dextran diffusion peaked at
45 min after thrombin treatment, decreased afterward continu-
ously, and after 210 min the diffusion rate of thrombin-treated
HUVECs was in the range of untreated controls. This find-
ing was very well reproduced using impedance-based measure-
ments. Time kinetic of the impedance curve mainly overlapped
with that of the transwell assay where impedance showed a peak
at around 45 min compared with an untreated cell and was re-
verted to the control level at around 210 min (Fig. 2B). We
further investigated batch-to-batch variability of HUVECs with
respect to their response to thrombin and IL-1, a cytokine in-
volved in induction of vascular leakage (Puhlmann et al., 2005;
Vandenbroucke et al., 2008). Figures 2C and 2D show two dif-
ferent batches of HUVECs treated with 2 U/ml thrombin or
10 ng/ml IL-1, respectively. Measured impedance of corre-
sponding wells within one experiment was very consistent and
showed low standard deviations between triplicates. Comparing
impedance curves of two different HUVEC batches showed that
the qualitative analysis of the impedance curve signature among
batches was comparable despite small shifts in time course or
curve maxima. However, this did not impact the assessment of
an increase of vascular permeability compared with untreated
controls.
Cytokine Receptor Expression in HUVECs
To further characterize and predict HUVEC responses to cy-
tokines and thrombin, we investigated the expression profiles
of corresponding receptors. As shown in Figure 3, HUVECs
exhibited high mRNA expression levels of the thrombin recep-
tor (F2R), the interferon gamma receptors 1 and 2 (IFNGR1,
IFNGR2), and the TNF- receptors 1A and 1B (TNFRSF1A,
TNFRSF1B). The typeI interleukin 1 receptor (IL-1R1), which
binds IL-1 and IL-1, was moderately expressed together with
its accessory transmembrane protein IL-1RAP. Not expressed
were the type 2 interleukin 1 scavenger receptor (IL-1R2) and
the heterotrimeric IL-2 receptor due to lack of expression of its
alpha subunit (IL-2RA), and barely expressed beta (IL-2RB)
and gamma (IL-2RG) subunits. The cytokine receptor com-
plexes for IL-6 and IL-10 showed an imbalanced subunit ex-
pression. The IL-6 receptor (IL-6R) was moderately expressed
whereas its subunit, the IL-6 signal transducer gp130 (IL-6ST),
was 16-fold higher expressed. The IL-10 receptor alpha subunit
showed low expression whereas the beta subunit was 12-fold
higher expressed. Based on this expression profile, we expected
substantial responses to TNF-, IFN- , IL-1, IL-6, IL-10, and
thrombin, whereas we did not expect responses to IL-2.
Impedance-Based Analysis of Cytokine-Induced Changes in
Vascular Permeability
We further investigated whether HUVECs were an ade-
quate model to measure changes of vascular permeability by
impedance technology. For this purpose, we treated a confluent
monolayer of HUVECs growing on E-Plates 96 with cytokines
or soluble factors for which we could demonstrate the presence
of its corresponding receptor (see Fig. 3) and/or which were
known to induce changes in vascular permeability. Impedance
was measured continuously over the following 13 h. To ensure
the specificity of our readout and to exclude compound-induced
changes in impedance not due to a dysregulation of tight and/or
adherens junction proteins, we compared side-by-side with a
confluent monolayer of a human fibroblast cell line CCD25-SK.
As shown before (see Fig. 1) CCD25-SK cells lack the expres-
sion of important adherens or tight junction proteins. Finally, to
distinguish CI changes subsequent to decrease in cell viability,
HUVECs were also treated with a cytotoxic agent (Triton X)
and impedance curves were compared. Results were displayed
as relative impedance changes to the untreated control.
First we analyzed thrombin, a compound which is known
to alter the tightness of the endothelium by calcium-dependent
mechanisms (Baumer et al., 2008). HUVECs responded to low
(0.2 U/ml) and intermediated (2 U/ml) doses of thrombin treat-
ment by a fast, dose-dependent decrease of impedance, which
was followed by a fast return to levels comparable to untreated
cells. By contrast, using the highest dose (20 U/ml) of throm-
bin the impedance failed to fully recover and levels remained
below that of untreated controls (see Fig. 4A). Importantly, hu-
man fibroblasts did not show a response to any of the three
thrombin concentrations (Fig. 4A). Next, IL-1, a cytokine that
is able to induce vascular leakage (Capaldo and Nusrat, 2009),
was assessed. At all three concentrations (1, 10, and 100 ng/ml)
HUVECs treated with IL-1 showed a similar response of the
impedance curve. Specifically, a sigmoid curve shape at the be-
ginning followed by a continuous drop of CI was observed (see
Fig. 4B). In contrast to HUVECs, IL-1 treatment of human
fibroblasts did not lead to a significant decrease of impedance
values (see Fig. 4B). Next, treatment of HUVECs with IFN- ,
another cytokine capable of inducing vascular leakage (Capaldo
and Nusrat, 2009), led to a continuous decrease in impedance up
to 5 h after treatment at 100, 1000, and 5000 U/ml followed by
recovery to control levels within the following 5 h (Fig. 4C).
CCD25-SK cells did not respond to IFN- incubation. TNF-
is also involved in increasing vascular permeability (Capaldo
and Nusrat, 2009; Seybold et al., 2005). HUVECs treated with
TNF- respond with a similar impedance curve pattern at 10,
100, and 500 ng/ml like those treated with IL-1 (Fig. 4D). In
contrast to that CCD25-SK cells responded to TNF- treatment
with a slight drop in impedance which went up to control levels
after 10 h (Fig. 4D). In summary, impedance analysis of TNF-
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FIG. 2. Comparison of a transwell diffusion assay and an impedance assay (A) and (B), and batch-to-batch variability of the impedance assay (C) and (D).
Time kinetics of diffusion of FITC-labelled Dextran through a monolayer of confluent HUVECs (A) is comparable to that of the impedance-based analysis (B),
i.e., an increasing loss of barrier integrity within the first 60 min followed by a decrease back to control levels after 3 h. Comparison of batch-to-batch variability
using two different batches of HUVECs treated with either thrombin (C) or IL-1 (D) at similar conditions shows that the quality of the readout is comparable
between different batches and both show a decrease in impedance with comparable time kinetics after treatment. Displayed are the average of n = 3 biological
replicates for (A), n = 4 for (B), n = 6 (LOT A) for (C) and (D), and n = 4 (LOT B) for (C) and (D), and each value is displayed ± standard deviation.
, IFN- , IL-1, and thrombin was well in line with receptor
expression data (see Fig. 3) which suggested a positive response
of HUVECs due to treatment with these cytokines and soluble
factors.
Second IL-2 and IL-6 were analyzed, both cytokines that play
a role in increasing vascular permeability as well (Capaldo and
Nusrat, 2009). Impedance analysis of IL-2 at 10, 100, and 500
ng/ml was well in line with the receptor expression profiles of
HUVECs (see Fig. 3) which suggested no response to IL-2 treat-
ment due to a lack of the corresponding receptors. Indeed, both
in HUVECs and in CCD25-SK cells we could not measure any
change in impedance after IL-2 treatment (see Fig. 4E). Unex-
pectedly, for IL-6 at 10, 100, and 500 ng/ml we could not mea-
sure any response of the impedance readout after IL-6 treatment
(see Fig. 4F), which was in contrast to the positive expression
of IL-6 receptors (see Fig. 3).
IL-10 is normally involved in increasing the tightness of the
vasculature (Capaldo and Nusrat, 2009; Oshima et al., 2001).
According to this, incubation of HUVECs with IL-10 at 10,
100, and 500 ng/ml did not lead to a decrease of impedance
but impedance remained stable apart from a short drop which
was fully reversible at the very beginning of the analysis (Fig.
4G). Fibroblasts incubated with IL-10 also did not respond to
treatment and impedance levels stayed constant over time (Fig.
4G). Finally, treatment of fibroblasts and HUVECs with a de-
tergent Triton X 100 at 0.01, 0.1, and 1% did lead to a drop of
impedance in both cell models in the same way, indicative of
a cell-type unspecific cytotoxic effect. Whereas the low con-
centration of Triton X 100 did induce only a slight drop of
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FIG. 3. Receptor expression in HUVECs. Gene expression signals of thrombin and cytokine receptors showing mean and standard deviations of three different
HUVEC batches. The detection limit of the microarray platform is indicated by a red dotted line; this signal is derived from 5000 random probes (60 mers of random
nucleotides), which serve as a metric of nonspecific annealing and background fluorescence.
impedance, the middle and the high dose led to an immediate,
irreversible drop of impedance (Fig. 4H).
Induced Vascular Permeability Could Be Reverted by Specific
Antagonists
The final step of assessing the impedance analysis was
whether nonspecific and specific antagonists of vascular leak
could prevent or revert drops in impedance following classi-
cal inducers. First, histamine induced a short, strong, and fully
reversible drop of the impedance (see Fig. 5A, blue line). Pre-
treatment of HUVECswith methylprednisolone 12 h before his-
tamine was added (time point histamine was added is indicated
with “1” in Fig. 5A) fully inhibited the histamine-induced drop
of the impedance curve (see Fig. 5A, red line). However, adding
methylprednisolone (time point methylprednisolone was added
is indicated with “3” in Fig. 5A) to HUVECs which had already
been cultured with histamine (time point histamine was added
is indicated with “2” in Fig. 5A) did not revert the impedance
effect of histamine (compare the blue line and the green line in
Fig. 5A). Administration of clemastine, a histamine receptor 1
antagonist (Peck et al., 1975), 12 h before histamine stimula-
tion of HUVECs (time point clemastine was added is indicated
with “1” in Fig. 5B) fully abolished the drop of impedance by
histamine (time point histamine was added is indicated with “2”
in Fig. 5B, red line). Like with methylprednisolone, addition of
clemastine to HUVECs (time point clemastine was added is in-
dicated with “3” in Fig. 5B) which had already been incubated
with histamine did not alter the impedance curve (Fig. 5B, green
line). Likewise, the IL-1-induced drop of impedance could
be abrogated by a pretreatment of HUVECs with anakinra,
an IL-1 receptor antagonist (Fig. 5C, red line; Cohen et al.,
2003). Furthermore, addition of anakinra to HUVECs which
had been treated with IL-1 before, led to reversion of the IL-1-
induced effect (Fig. 5C, green line). The TNF--induced drop
of impedance could be completely abrogated by pretreatment of
HUVECs with Remicade, a neutralizing monoclonal antibody
against human TNF- (Fig. 5D, red line; Maini et al., 1998).
Addition of Remicade to HUVECs which had already been in-
cubated with TNF- led to a rescue and impedance went up to
control level (Fig. 5D, green line). High content analysis at the
end of the experiment for cell death did not show a significant
increase in cell death due to the different compounds analyzed
by a one-way ANOVA (analysis of variance) and a Dunnett
post-test.Apart from TNF- alone, none of the other treatments
increased the percentage of dead cell content per well compared
with the untreated controls (Fig. 5E). However, the fact that
the impedance curve after addition of Remicade reached a level
comparable to that of pretreated conditions strongly suggests
real functional antagonism rather than differences in the dead
cell content.
DISCUSSION
The goal of the present study was to design an in vitro sys-
tem to accurately assess the ability of a therapeutic compound
to alter the endothelial monolayer integrity. In order to pre-
dict vascular leak in vivo we established a reliable and rapid in
vitro assay using HUVECs as a model of the endothelium. We
could demonstrate their relevance because they expressed ma-
jor junctional proteins responsible for maintaining the tightness
of the endothelium including receptors for most cytokines re-
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FIG. 4. Impedance-based vascular leakage assay: Impedance based analysis for vascular leakage induced by thrombin, IL-1, IFN- , TNF-, IL-2, IL-6,
IL-10, and Triton-X 100. HUVECs or CCD25-SK as a nonresponder cell line are incubated with the different compounds at three different concentration (for
details please refer to the Materials and Methods section): low concentration (blue line), medium concentration (red line), and high concentration (green line), and
impedance was continuously measured the following hours. Each line represents the average of one experiment with n = 6 biological replicate wells (except for
(H) HUVEC n = 4). Each experiment has been repeated twice and graphs are representative for both experiments.
sponsible for increased vascular permeability. We introduced
an impedance-based platform to capture compound induced
changes in endothelial barrier function and could prove that re-
sults were fully concordant to those measured by a standard
transwell chamber vascular permeability assay. In addition, our
assay is a noninvasive, highly reproducible method that allows
real-time kinetics, dose-effect comparison, parallel recording
of different treatments, and semiquantitative assessment rela-
tive to controls in a very efficient way. Our assay approach in-
cluded testing compounds in parallel on nonresponder human
fibroblast cells which did increase specificity to predict vascu-
lar leakage by excluding direct cytotoxic events underlying the
impedance curve changes. Furthermore, by treatment of cells
with antagonists for histamine, IL-1, or TNF-we could com-
pletely block the impedance drop in vitro and IL-1 or TNF--
induced vascular leakage could even be reverted by addition of
rheumatoid arthritis drugs anakinra or Remicade to the cells.
This further underlines the biological relevance of the estab-
lished assay in terms of the chosen cellular model HUVEC as
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FIG. 5. Antagonization of vascular leakage by antagonists: Antagonization of histamine, IL-1, or TNF--induced vascular permeability. HUVECs are
treated with histamine, IL-1, or TNF- [indicated as “2” in (A)–(D)], which induces vascular leakage [blue line; (A)–(D)]. Vascular leakage shown as decrease
impedance values is abrogated by a preceding addition of the corresponding antagonist at time point “1” [red line; (A)–(D)]. Post-treatment of HUVECs after
incubation with histamine, IL-1, or TNF- with the corresponding antagonists at time point “3” does not revert the histamine effect but that of IL-1 and TNF-,
where impedance levels increase back to pretreatment levels [green line; (A)–(D)]. Displayed is the average of n = 4 biological replicates for each experiment.
(E) Cytotoxicity analysis using high-content imaging 24 h after post-treatment of cells with the corresponding antagonist as shown in (A)–(D) reveals that only
incubation of HUVECs with TNF- alone increases the number of dead cells compared with controls. Any other treatment is not raising the number of dead cells
compared with untreated controls. Displayed are the average values of n = 4 biological replicates ± standard deviation.
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well as the real-time, impedance-based readout to predict clini-
cally relevant drug-induced vascular permeability.
In mammals, proinflammatory cytokines and other vasoac-
tive substances have been shown to increase permeability of the
endothelium by directly interacting with receptors on the sur-
face of endothelial cells (Capaldo and Nusrat, 2009). Through
various mechanisms this may lead to a disassembly of cell-cell
junctional proteins and to remodeling of the actin cytoskele-
ton which are considered key events in the early stages of vas-
cular leakage (Vandenbroucke et al., 2008). In our model, we
could demonstrate that HUVECs successfully establish tight
and adherens junctions revealed by an expression of ZO-1, VE-
Cadherin, and Claudin 5 which is in concordance with previ-
ously published work using HUVECs as a model of the en-
dothelium (Baumer et al., 2010) underlying the relevance of
our established in vitro system. After incubation with thrombin
for 30 min HUVECs displayed fragmentation of tight and ad-
herens junction expression pattern as revealed by a ZO-1, VE-
Cadherin, and Claudin 5 staining (Fig. 1). Additionally, actin
staining revealed appearance of multiple stress fibers (Fig. 1D)
which is in line with previous data as well demonstrating frag-
mentation of VE-Cadherin staining and increase in actin stress
fibers in human dermal microvascular endothelial cells upon
thrombin treatment (Baumer et al., 2008).
Multiple cytokines and other soluble factors have been iden-
tified which could induce vascular permeability, including IL-2
and IL-6 (Capaldo and Nusrat, 2009). Although the in vivo ef-
fect of IL-1, TNF-, IFN- , histamine, and thrombin could
be recapitulated in our model, an increase of vascular perme-
ability using IL-2 or IL-6 could not be observed (Fig. 4). With
respect to IL-2, this result is in line with previously published
and with our current data showing lack of IL-2 receptor expres-
sion on HUVECs (Dewi et al., 2004). Additionally, it is still not
fully established whether IL-2-induced vascular leakage is due
to direct interaction with endothelial cells or indirectly via inter-
action of IL-2 via activated neutrophils, which were not present
in our assay system (Baluna, 2007; Capaldo and Nusrat, 2009).
The lack of response of HUVECs to IL-6 is in contrast to an-
other publication demonstrating IL-6-mediated increase in per-
meability (Desai et al., 2002) and also not in line with our data
showing IL-6 receptor subunit expression on the cells. It could
be speculated that HUVECs used in the present system do not
allow efficient IL-6 receptor complex assembly due to imbal-
anced expression of the receptor subunits or due to a lack in
lipid rafts or protein sorting into lipid rafts, which is necessary
for proper IL-6 signaling (Buk et al., 2005).
In contrast to other approaches aiming to assess vascular per-
meability relying on endothelial cells only (Ludwig et al., 2011),
we have included here a negative control cell model, i.e., hu-
man skin fibroblasts, which do not express Claudin 5 or VE-
Cadherin (Fig. 1; Furuse et al., 1998). Thus, comparison of
impedance curves of HUVECs versus fibroblasts was used to
exclude unspecific effects on cellular morphology by processes
other than those affecting cell-cell junctions. Incubation of fi-
broblasts with cytokines or thrombin did not alter impedance
confirming that modulation of cell-cell junctions in HUVECs
reflects a key step in the development of vascular leakage. It
should be noted though that IFN- did induce a slight increase
in impedance which is normally indicative of increase prolif-
eration compared with control. This observation is in line with
a publication describing an increase in proliferation of slowly
dividing fibroblasts after IFN- treatment (Elias et al., 1987).
We propose that it is an effect on fibroblast morphology rather
than a true proliferative response, which is supported by the fact
that fibroblast cultures were confluent at the time point of treat-
ment making an increase of proliferation unlikely. Thus, our re-
sults demonstrate the importance of including an additional cell
model which serves as a negative control to exclude unspecific
effects.
A key aspect of the present study was to show physiological
relevance and specificity of the model by being able to inhibit or
reverse vascular leakage induced by histamine, IL-1, or TNF-
 using established drugs (Fig. 5). Only for histamine we could
not revert the effect by addition of either methylprednisolone or
clemastine directly after histamine treatment to the cells. On the
other hand, pretreatment of HUVECs with Methylpredisolone
and clemastine did completely inhibit leakage. The lack of re-
sponse might be due to a very short half-life of the histamine
effect per se where the induced leakage is back to control levels
already 90 min after the onset of the effect. Given this, it would
be almost impossible to revert such an effect on an in vitro level.
Additional analysis of cytotoxicity revealed that both inducers
and inhibitors of vascular leakage did not induce a significant
effect as shown by HCI (high content imaging) analysis further
excluding unspecific changes introducing bias.
Taken together, the present study shows for the first time a
comprehensive analysis of several cytokines and an additional
soluble factor for the induction of vascular permeability using
impedance analysis. HUVECs in combination with impedance
measurements are a well-suited model to measure increase in
vascular leakage in real time. By including fibroblasts devoid
of junction proteins, we were able to differentiate endothelial-
cell specific from unspecific cellular effects. Additionally, we
were able to specifically revert the induction of vascular leak-
age using established antagonists. The assay is simple to use and
showed excellent reproducibility with a meaningful through-
put. In biopharmaceutical industry, it could be used to test drug
candidates for their potential to induce vascular leakage via di-
rect effects on endothelial cells. Additionally, our approach has
shown its applicability to test clinically relevant counter mea-
sures for a drug-induced vascular leakage. The platform also
bears the potential to be adapted to several target organs: e.g., it
could be used to test drug-induced vascular leakage in the eye
which bears a high risk for induction of severe visual impair-
ment by inducing macular edema (Makri et al., 2013). Thus,
impedance-based analysis of vascular leakage is a well suited
tool to test drugs for their potential to increase vascular leakage
early on in drug development.
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